Pentoxifylline

INQUIRY Add to cart

For Research Use Only | Not For Clinical Use

CAT	APS6493056
CAS	6493-05-6
Structure
MDL Number	MFCD00063379
Synonyms	3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione, Pentoxifylline,1-(5-Oxohexyl)-3,7-dimethylxanthine, NSC 637086, Pexal, Pentoxiphylline, Torental, Rentylin, Trental, Vasotal, Pentoxyphyllin, Vazofirin, Durapental, PTX, Oxpentifylline, Agapurin Retard, Pentoxifyllin, 3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione, Pentoxyfilline, Dimethyloxohexylxanthine, 1-(5-Oxohexyl)theobromine, Azupentat, BL 191, 3,7-Dimethyl-1-(5-oxohexyl)xanthine, Pentoxiphyllin, Agapurin
IUPAC Name	3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
Molecular Weight	278.31
Molecular Formula	C13H18N4O3
EC Number	229-374-5
Canonical SMILES	CN1C(=O)N(CCCCC(=O)C)C(=O)c2c1ncn2C
InChI	InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
InChI Key	MQGNNJQTNFHNHK-UHFFFAOYSA-N

Description	solid
Solubility	H2O: ≥43 mg/mL
Accurate Mass	278.1379
Color	white
Form	solid
Format	Neat
Size	10G, 100G, 250G

* Products or Services Interested: Pentoxifylline (6493-05-6)
* Your question
* Name
* Email
Verification Code

CAT	Size	Shipping	Storage Conditions	Description	Price
APS6493056-1	100MG	Room Temperature	+20°C	Subcategory: Pharmaceutical and veterinary compounds and metabolites	Inquiry
APS6493056-2	100MG	Room Temperature	2-8°C Fridge/Coldroom	Subcategory: European Pharmacopoeia (Ph. Eur.); API Family: Matrix - API Family See respective official monograph(s); Product Type: API	Inquiry
APS6493056-3	500MG	Room Temperature	+5°C	Subcategory: API standards, Cardiac drugs and beta blockers, Mikromol; API Family: Matrix - API Family Pentoxifylline; Product Type: API	Inquiry

Case Study

Pentoxifylline Used for the Preparation of Dual-Drug Liposomal Gels for Burn Wound Treatment

El-Salamouni, Noha S., et al. International Journal of Pharmaceutics 625 (2022): 122129.

Pentoxifylline (PTX), a methylxanthine derivative with anti-inflammatory and hemorheological properties, has shown therapeutic promise in the treatment of burn injuries. In a recent formulation strategy, PTX was co-encapsulated with valsartan (VAL) into phospholipid-based liposomes to create a novel dual-drug delivery system designed specifically for burn wound applications.
The liposomes were fabricated using a lipid film hydration method with Lipoid S100 and cholesterol (4:1 w/w) as the lipid matrix. VAL was first dissolved in chloroform with lipids, and a thin lipid film was formed via rotary evaporation. This film was subsequently hydrated using an aqueous PTX solution (1% w/w in phosphate buffer, pH 6.8), followed by rotary mixing and sonication to ensure efficient encapsulation. The resulting pentoxifylline-valsartan liposomes (PTX-VAL-L) were then incorporated into a gel matrix to enable topical application.
This co-delivery system leverages the complementary therapeutic effects of PTX (anti-inflammatory and vasodilatory) and VAL (angiotensin II receptor antagonist), offering enhanced wound healing, reduced inflammation, and improved vascularization at the burn site. The study underscores PTX's critical role not only as a bioactive molecule but also as a component in the development of advanced drug delivery platforms for trauma care.
This formulation exemplifies PTX's potential in modern nanocarrier-based therapeutics for complex wound management.

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.

Online Inquiry